| Diastolic Blood Pressure as a Biomarker of Axitinib Efficacy in Solid Tumors. | |
| | |
MedLine Citation:
|
PMID: 21531811 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
PURPOSE: To evaluate if diastolic blood pressure (dBP) ≥90 mm Hg during axitinib treatment is a marker of efficacy. EXPERIMENTAL DESIGN: The relationship between dBP ≥90 mm Hg and efficacy was retrospectively explored across five phase II studies of single-agent axitinib for the treatment of four different tumor types. All patients had baseline BP ≤140/90 mm Hg and were stratified into two groups based upon in-clinic BP measurements after initiating therapy: those with dBP <90 mm Hg throughout therapy and those with at least one dBP ≥90 mm Hg. Median overall survival (mOS), median progression-free survival (mPFS), objective response rate (ORR), and adverse events were evaluated by dBP group in individual and pooled analyses. RESULTS: Two-hundred thirty patients were evaluated. Patients with dBP ≥90 mm Hg had significantly longer mOS than those with dBP <90 mm Hg (30.1 versus 10.2 months; adjusted hazard ratio [HR] [95% confidence interval (CI)] = 0.55 [0.39, 0.77]; P < 0.001); mPFS was twofold longer in patients with dBP ≥90 mm Hg (13.1 versus 5.8 months; HR [95% CI] = 0.76 [0.54, 1.06], P = 0.107), and ORR was significantly higher (43.9% versus 12.0%; P < 0.001). In an 8-week landmark analysis, mOS (25.8 versus 14.9 months) and mPFS (10.2 versus 7.1 months) were greater for patients in the ≥90-mm Hg group. Adverse events were similar between groups.CONCLUSIONS: Axitinib efficacy correlated with dBP ≥90 mm Hg. Further investigation of dBP as a predictive biomarker of efficacy in patients receiving axitinib is warranted. |
| | |
Authors:
|
Brian I Rini; Joan H Schiller; John P Fruehauf; Ezra Ew Cohen; Jamal C Tarazi; Brad Rosbrook; Angel H Bair; Alejandro D Ricart; Anthony J Olszanski; Kristen J Letrent; Sinil Kim; Olivier Rixe |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-4-29 |
Journal Detail:
|
Title: Clinical cancer research : an official journal of the American Association for Cancer Research Volume: - ISSN: 1078-0432 ISO Abbreviation: - Publication Date: 2011 Apr |
Date Detail:
|
Created Date: 2011-5-2 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9502500 Medline TA: Clin Cancer Res Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Effectiveness of tyrosine kinase inhibitors on uncommon epidermal growth factor receptor mutations o...
Next Document: A low-toxicity IL-2 based immunocytokine retains anti-tumor activity despite its high degree of IL-2...